STOCK TITAN

Innospec Inc Financials

IOSP
FY2025 annual
Revenue $1.8B -3.7% YoY
Net Income $116.6M +227.5% YoY
EPS (Diluted) $4.67 +228.9% YoY
Free Cash Flow Not reported for FY2025
Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Innospec Inc (IOSP) reported $1.8B in revenue for fiscal year 2025, down 3.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IOSP FY2025

Cash-rich balance-sheet discipline is cushioning a margin-led revenue slowdown, keeping operations flexible without obvious balance-sheet strain as the earnings engine softens.

The least obvious pattern is that cash conversion stayed intact even as reported profit swung sharply: in FY2024, operating cash flow was $184.5M against net income of $35.6M. In FY2025, the same relationship held at $138.3M versus $116.6M, so the prior earnings drop looked less like a funding problem than a mismatch between accounting profit and operating cash.

Core operating pressure looks more persistent than the net-income rebound implies, because revenue slipped from $1.95B to $1.78B. Gross margin compression from 30.3% to 27.7% shows the earnings recovery did not come from a stronger underlying cost position.

Balance-sheet posture remained conservative rather than defensive: cash reached $292.5M and total liabilities fell to $499.5M. But working capital absorbed more cash as inventory rose to $329.3M while operating cash flow eased to $138.3M.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 51 / 100
Financial Health Score 51/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Innospec Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
72

Innospec Inc has an operating margin of 7.3%, meaning the company retains $7 of operating profit per $100 of revenue. This strong profitability earns a score of 72/100, reflecting efficient cost management and pricing power. This is down from 9.6% the prior year.

Growth
19

Innospec Inc's revenue declined 3.7% year-over-year, from $1.8B to $1.8B. This contraction results in a growth score of 19/100.

Leverage
64

Innospec Inc has a moderate D/E ratio of 0.38. This balance of debt and equity financing earns a leverage score of 64/100.

Liquidity
74

With a current ratio of 2.79, Innospec Inc holds $2.79 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 74/100.

Cash Flow
0

Not available for Innospec Inc, and counted as zero in the overall score.

Returns
75

Innospec Inc earns a strong 8.8% return on equity (ROE), meaning it generates $9 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 75/100. This is up from 2.9% the prior year.

Altman Z-Score Safe
5.30

Innospec Inc scores 5.30, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($2.4B) relative to total liabilities ($499.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
6/8

Innospec Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed
1.19x

For every $1 of reported earnings, Innospec Inc generates $1.19 in operating cash flow ($138.3M OCF vs $116.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.8B
YoY-3.7%
5Y CAGR+8.3%
10Y CAGR+5.8%

Innospec Inc generated $1.8B in revenue in fiscal year 2025. This represents a decrease of 3.7% from the prior year.

EBITDA
$173.1M
YoY-21.8%
5Y CAGR+16.8%
10Y CAGR-1.0%

Innospec Inc's EBITDA was $173.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.8% from the prior year.

Net Income
$116.6M
YoY+227.5%
5Y CAGR+32.4%
10Y CAGR-0.2%

Innospec Inc reported $116.6M in net income in fiscal year 2025. This represents an increase of 227.5% from the prior year.

EPS (Diluted)
$4.67
YoY+228.9%
5Y CAGR+32.1%
10Y CAGR-0.4%

Innospec Inc earned $4.67 per diluted share (EPS) in fiscal year 2025. This represents an increase of 228.9% from the prior year.

Cash & Balance Sheet

Cash & Debt
$292.5M
YoY+1.1%
5Y CAGR+22.7%
10Y CAGR+7.9%

Innospec Inc held $292.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Dividends Per Share
$1.71
YoY+10.3%
5Y CAGR+10.5%
10Y CAGR+10.9%

Innospec Inc paid $1.71 per share in dividends in fiscal year 2025. This represents an increase of 10.3% from the prior year.

Shares Outstanding
25M
YoY-0.7%
5Y CAGR+0.1%
10Y CAGR+0.3%

Innospec Inc had 25M shares outstanding in fiscal year 2025. This represents a decrease of 0.7% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
27.7%
YoY-1.7pp
5Y CAGR-1.0pp
10Y CAGR-6.5pp

Innospec Inc's gross margin was 27.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.7 percentage points from the prior year.

Operating Margin
7.3%
YoY-2.4pp
5Y CAGR+4.5pp
10Y CAGR-8.2pp

Innospec Inc's operating margin was 7.3% in fiscal year 2025, reflecting core business profitability. This is down 2.4 percentage points from the prior year.

Net Margin
6.6%
YoY+4.6pp
5Y CAGR+4.2pp
10Y CAGR-5.2pp

Innospec Inc's net profit margin was 6.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.6 percentage points from the prior year.

Return on Equity
8.8%
YoY+5.9pp
5Y CAGR+5.8pp

Innospec Inc's ROE was 8.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.9 percentage points from the prior year.

Capital Allocation

R&D Spending
$51.0M
YoY-9.7%
5Y CAGR+10.5%
10Y CAGR+7.3%

Innospec Inc invested $51.0M in research and development in fiscal year 2025. This represents a decrease of 9.7% from the prior year.

Share Buybacks
$23.9M
YoY+3314.3%
5Y CAGR+62.6%
10Y CAGR+4.6%

Innospec Inc spent $23.9M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 3314.3% from the prior year.

Capital Expenditures

Not reported for fiscal year 2025.

IOSP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IOSP annual income statement
MetricTTMFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Revenue$1.8B$1.8B-3.7%$1.8B-5.3%$1.9B-0.8%$2.0B+32.4%$1.5B+24.3%$1.2B-21.2%$1.5B+2.5%$1.5B+13.0%$1.3B+47.9%$883.4M-12.7%$1.0B+5.3%$960.9M+17.4%$818.8M+5.5%$776.4M+0.3%$774.4M
Cost of Revenue$1.3B$1.3B-1.3%$1.3B-4.1%$1.4B-1.4%$1.4B+31.3%$1.0B+23.3%$850.4M-18.8%$1.0B+0.5%$1.0B+15.3%$903.5M+63.9%$551.1M-17.3%$666.3M+1.1%$658.9M+16.9%$563.6M+4.4%$540.0M-1.5%$548.0M
Gross Profit$505.9M$492.4M-9.3%$542.9M-8.2%$591.1M+0.7%$586.7M+34.9%$434.9M+26.9%$342.7M-26.5%$466.2M+7.2%$435.0M+7.9%$403.3M+21.4%$332.3M-4.0%$346.0M+14.6%$302.0M+18.3%$255.2M+8.0%$236.4M+4.4%$226.4M
R&D Expenses$52.1M$51.0M-9.7%$56.5M+15.3%$49.0M+26.6%$38.7M+3.5%$37.4M+21.0%$30.9M-12.7%$35.4M+6.0%$33.4M+6.4%$31.4M+23.6%$25.4M+0.4%$25.3M+14.0%$22.2M+4.7%$21.2M+8.2%$19.6M+7.1%$18.3M
SG&A Expenses$304.0M$285.1M-6.6%$305.3M-19.8%$380.5M+5.5%$360.7M+35.0%$267.2M+12.7%$237.0M-15.6%$280.9M+7.6%$261.0M+6.9%$244.2M+12.7%$216.7M+4.8%$206.7M+22.2%$169.2M+19.1%$142.1M+19.3%$119.1M-24.8%$158.3M
Operating Income$128.9M$129.5M-27.2%$177.9M+10.1%$161.6M-13.7%$187.3M+41.8%$132.1M+292.0%$33.7M-77.5%$149.9M+12.3%$133.5M+6.8%$125.0M+27.3%$98.2M-37.2%$156.3M+38.9%$112.5M+24.2%$90.6M-6.1%$96.5M+104.4%$47.2M
Interest ExpenseN/A$0$0$0$0$0-100.0%$800K-83.3%$4.8M-26.2%$6.5M-9.7%$7.2M+176.9%$2.6M+13.0%$2.3M-39.5%$3.8M+65.2%$2.3M+27.8%$1.8M-53.8%$3.9M
Income Tax$21.0M$21.5M+283.9%$5.6M-84.1%$35.3M-31.6%$51.6M+24.9%$41.3M+275.5%$11.0M-71.2%$38.2M-18.0%$46.6M-29.7%$66.3M+204.1%$21.8M-33.5%$32.8M+22.4%$26.8M+78.7%$15.0M-43.2%$26.4M+751.6%$3.1M
Net Income$121.5M$116.6M+227.5%$35.6M-74.4%$139.1M+4.6%$133.0M+42.9%$93.1M+224.4%$28.7M-74.4%$112.2M+32.0%$85.0M+37.5%$61.8M-24.0%$81.3M-32.0%$119.5M+42.1%$84.1M+8.1%$77.8M+16.3%$66.9M+42.0%$47.1M
EPS (Diluted)$4.67+228.9%$1.42-74.5%$5.56+4.5%$5.32+41.9%$3.75+223.3%$1.16-74.4%$4.54+31.6%$3.45+36.9%$2.52-24.3%$3.33-31.5%$4.86+43.8%$3.38+5.0%$3.22+14.6%$2.81+46.4%$1.92

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

IOSP Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IOSP annual balance sheet
MetricFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Total Assets$1.8B+5.6%$1.7B+1.6%$1.7B+6.5%$1.6B+2.1%$1.6B+12.4%$1.4B-4.9%$1.5B-0.3%$1.5B+4.5%$1.4B+19.4%$1.2B+14.9%$1.0B+2.9%$999.9M+25.8%$794.7M+37.2%$579.4M+1.9%$568.8M
Current Assets$1.0B+5.0%$956.6M+8.0%$885.7M+1.5%$872.6M+19.8%$728.1M+28.6%$566.2M-10.2%$630.3M-5.1%$663.9M+18.2%$561.5M+27.3%$441.1M-3.8%$458.7M+10.7%$414.2M+1.7%$407.4M+37.4%$296.6M-7.4%$320.3M
Cash & Equivalents$292.5M+1.1%$289.2M+42.0%$203.7M+38.5%$147.1M+3.7%$141.8M+34.7%$105.3M+39.1%$75.7M-38.5%$123.1M+36.5%$90.2M-11.5%$101.9M-25.6%$136.9M+229.1%$41.6M-48.1%$80.2M+258.0%$22.4M-70.6%$76.2M
Inventory$329.3M+9.4%$301.0M+0.3%$300.1M-19.6%$373.1M+34.4%$277.6M+26.2%$220.0M-10.1%$244.6M-1.4%$248.0M+18.2%$209.8M+20.7%$173.8M+8.7%$159.9M-13.5%$184.9M+16.4%$158.9M+14.9%$138.3M+1.8%$135.9M
Goodwill$399.0M+4.3%$382.5M-4.2%$399.3M+11.3%$358.8M-1.5%$364.3M-1.9%$371.2M+2.3%$363.0M-0.5%$364.9M+0.9%$361.8M-3.5%$374.8M+40.2%$267.4M-3.2%$276.1M+46.9%$187.9M+26.1%$149.0M+5.3%$141.5M
Total Liabilities$499.5M-3.7%$518.6M-7.0%$557.8M-1.0%$563.3M+4.7%$537.9M+18.7%$453.0M-70.6%$1.5B+138.2%$647.9M+5.2%$615.9M+16.7%$527.6M+24.2%$424.7M-12.3%$484.0M+25.6%$385.3M+46.8%$262.4M+16.3%$225.7M
Current Liabilities$360.1M-3.0%$371.4M0.0%$371.5M-8.5%$405.8M+20.6%$336.6M+33.4%$252.4M-16.8%$303.5M+2.3%$296.6M+13.4%$261.5M+42.8%$183.1M-11.2%$206.1M-7.5%$222.9M+43.3%$155.6M+5.6%$147.3M+0.9%$146.0M
Long-Term DebtN/AN/AN/AN/AN/A$0-100.0%$58.6M-68.5%$186.2M-8.1%$202.6M-21.6%$258.5M+96.4%$131.6M-5.3%$139.0M-2.6%$142.7M+470.8%$25.0M-16.7%$30.0M
Total Equity$1.3B+9.5%$1.2B+5.6%$1.1B+10.5%$1.0B+0.5%$1.0B+9.3%$944.4M+1369.4%-$74.4M-109.0%$825.0M+3.9%$793.9M+21.5%$653.5M+8.0%$605.0M+17.3%$515.9M+26.0%$409.4M+29.1%$317.0M-7.6%$343.1M
Retained Earnings$1.1B+7.2%$1.0B-0.3%$1.0B+11.3%$924.2M+12.3%$822.9M+8.5%$758.6M+0.4%$755.5M+13.0%$668.3M+10.5%$605.0M+7.7%$561.8M+13.2%$496.4M+26.7%$391.8M+22.5%$319.9M+22.2%$261.7M+8.4%$241.5M

Not reported in any period shown, so not listed: Accounts Receivable.

IOSP Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

IOSP annual cash flow statement
MetricTTMFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Operating Cash Flow$124.3M$138.3M-25.0%$184.5M-11.0%$207.3M+153.7%$81.7M-12.3%$93.2M-36.1%$145.9M-9.7%$161.6M+54.1%$104.9M+26.8%$82.7M-21.6%$105.5M-10.7%$118.2M+11.2%$106.3M+73.4%$61.3M0.0%$61.3M+76.7%$34.7M
Capital ExpendituresN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$17.6M+30.4%$13.5M+22.7%$11.0M+27.9%$8.6M+22.9%$7.0M
Free Cash FlowN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$100.6M+8.4%$92.8M+84.5%$50.3M-4.6%$52.7M+90.3%$27.7M
Investing Cash Flow-$73.6M-$75.1M-21.1%-$62.0M+44.5%-$111.8M-165.6%-$42.1M-16.3%-$36.2M-21.9%-$29.7M+4.2%-$31.0M+12.7%-$35.5M-19.9%-$29.6M+85.8%-$209.1MN/AN/A-$116.1M-65.1%-$70.3M-557.0%-$10.7M
Financing Cash Flow-$66.3M-$63.9M-81.0%-$35.3M+9.5%-$39.0M-15.7%-$33.7M-68.5%-$20.0M+77.0%-$86.8M+51.2%-$177.9M-391.4%-$36.2M+45.5%-$66.4M-195.5%$69.5MN/AN/A$112.8M+352.3%-$44.7M+18.7%-$55.0M
Dividends PaidN/A$42.4M+9.3%$38.8M+10.5%$35.1M+10.7%$31.7M+10.1%$28.8M+12.5%$25.6M+2.4%$25.0M+15.2%$21.7M+16.7%$18.6M+17.0%$15.9M+6.7%$14.9M+11.2%$13.4M+11.7%$12.0M-74.3%$46.7M$0
Share Buybacks$24.1M$23.9M+3314.3%$700K-36.4%$1.1M-81.4%$5.9M+637.5%$800K-61.9%$2.1M-12.5%$2.4M+71.4%$1.4M+27.3%$1.1M-86.9%$8.4M-45.1%$15.3M+121.7%$6.9M+86.5%$3.7M+164.3%$1.4M-95.0%$28.1M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

IOSP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

IOSP annual financial ratios
MetricFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Gross Margin27.7%-1.7pp29.4%-0.9pp30.3%+0.5pp29.9%+0.6pp29.3%+0.6pp28.7%-2.1pp30.8%+1.4pp29.4%-1.4pp30.9%-6.8pp37.6%+3.4pp34.2%+2.7pp31.4%+0.3pp31.2%+0.7pp30.4%+1.2pp29.2%
Operating Margin7.3%-2.4pp9.6%+1.3pp8.3%-1.2pp9.5%+0.6pp8.9%+6.1pp2.8%-7.1pp9.9%+0.9pp9.0%-0.5pp9.6%-1.6pp11.1%-4.3pp15.4%+3.7pp11.7%+0.6pp11.1%-1.4pp12.4%+6.3pp6.1%
Net Margin6.6%+4.6pp1.9%-5.2pp7.1%+0.4pp6.8%+0.5pp6.3%+3.9pp2.4%-5.0pp7.4%+1.7pp5.8%+1.0pp4.7%-4.5pp9.2%-2.6pp11.8%+3.0pp8.8%-0.8pp9.5%+0.9pp8.6%+2.5pp6.1%
Return on Equity8.8%+5.9pp2.9%-9.2pp12.1%-0.7pp12.8%+3.8pp9.0%+6.0pp3.0%N/A10.3%+2.5pp7.8%-4.7pp12.4%-7.3pp19.8%+3.5pp16.3%-2.7pp19.0%-2.1pp21.1%+7.4pp13.7%
Return on Assets6.4%+4.3pp2.1%-6.1pp8.2%-0.1pp8.3%+2.4pp5.9%+3.9pp2.1%-5.6pp7.6%+1.9pp5.8%+1.4pp4.4%-2.5pp6.9%-4.7pp11.6%+3.2pp8.4%-1.4pp9.8%-1.8pp11.6%+3.3pp8.3%
Current Ratio2.79+0.2x2.58+0.2x2.38+0.2x2.150.0x2.16-0.1x2.24+0.2x2.08-0.2x2.24+0.1x2.15-0.3x2.41+0.2x2.23+0.4x1.86-0.8x2.62+0.6x2.01-0.2x2.19
Debt-to-Equity0.38-0.1x0.43-0.1x0.49-0.1x0.540.0x0.52+0.5x0.00N/A0.230.0x0.26-0.1x0.40+0.2x0.22-0.1x0.27-0.1x0.35+0.3x0.080.0x0.09
FCF MarginN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A9.9%+0.3pp9.7%+3.5pp6.1%-0.6pp6.8%+3.2pp3.6%

Similar Companies

Frequently Asked Questions

What is Innospec Inc's annual revenue?

Innospec Inc (IOSP) reported $1.8B in total revenue for fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Innospec Inc's revenue growing?

Innospec Inc (IOSP) revenue declined by 3.7% year-over-year, from $1.8B to $1.8B in fiscal year 2025.

Is Innospec Inc profitable?

Yes, Innospec Inc (IOSP) reported a net income of $116.6M in fiscal year 2025, with a net profit margin of 6.6%.

Innospec Inc (IOSP) reported diluted earnings per share of $4.67 for fiscal year 2025. This represents a 228.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Innospec Inc (IOSP) had EBITDA of $173.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Innospec Inc (IOSP) had a gross margin of 27.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Innospec Inc (IOSP) had an operating margin of 7.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Innospec Inc (IOSP) had a net profit margin of 6.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Innospec Inc (IOSP) paid $1.71 per share in dividends during fiscal year 2025.

Innospec Inc (IOSP) has a return on equity of 8.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Innospec Inc (IOSP) generated $138.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Innospec Inc (IOSP) had $1.8B in total assets as of fiscal year 2025, including both current and long-term assets.

Innospec Inc (IOSP) invested $51.0M in research and development during fiscal year 2025.

Yes, Innospec Inc (IOSP) spent $23.9M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Innospec Inc (IOSP) had 25M shares outstanding as of fiscal year 2025.

Innospec Inc (IOSP) had a current ratio of 2.79 as of fiscal year 2025, which is generally considered healthy.

Innospec Inc (IOSP) had a debt-to-equity ratio of 0.38 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Innospec Inc (IOSP) had a return on assets of 6.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Innospec Inc (IOSP) has an Altman Z-Score of 5.30, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Innospec Inc (IOSP) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Innospec Inc (IOSP) has an earnings quality ratio of 1.19x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Innospec Inc (IOSP) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top